The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical and preclinical activity of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk of hematologic malignancies, against blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Arthur E. Frankel
Research Funding - Stemline Therapeutics
Jung Hee Woo
No relevant relationships to disclose
Jeremy Preston Mauldin
No relevant relationships to disclose
Hetty Eileen Carraway
No relevant relationships to disclose
Olga Frankfurt
No relevant relationships to disclose
Stephen J. Forman
No relevant relationships to disclose
Christopher Brooks
Employment or Leadership Position - Stemline Therapeutics
Ivan Bergstein
Employment or Leadership Position - Stemline Therapeutics
Stock Ownership - Stemline Therapeutics (B)
Thomas Cirrito
Employment or Leadership Position - Stemline Therapeutics
Stock Ownership - Stemline Therapeutics (B)
Eric K. Rowinsky
Employment or Leadership Position - Stemline Therapeutics
Stock Ownership - Stemline Therapeutics (B)